Clinical Trials Logo

Advanced Mucosal Melanoma clinical trials

View clinical trials related to Advanced Mucosal Melanoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03941795 Recruiting - Clinical trials for Advanced Mucosal Melanoma

Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma

BJCH-MM-0624
Start date: November 11, 2019
Phase: Phase 2
Study type: Interventional

This is a randomized, controlled, multicenter Phase II clinical study to evaluate the efficacy and safety of toripalimab injection combined with axitinib in the first-line treatment of patients with advanced mucosal melanoma. The target population is the patients with previously untreated, histopathologically confirmed, unresectable or metastatic mucosal melanoma. At the randomization, patients are randomized 1:1:1 into three groups with approximately 33 subjects in each group to receive toripalimab injection plus axitinib, toripalimab injection monotherapy (subjects who meet the criteria after disease progression may cross over to receive toripalimab plus axitinib), or axitinib monotherapy (subjects who meet the criteria after disease progression may cross over to receive toripalimab plus axitinib); when the patient has disease progression or intolerable toxicity, the treatment is terminated, and the survival follow-up will be initiated.